Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate Academic Article uri icon

Overview

MeSH Major

  • Acetylmuramyl-Alanyl-Isoglutamine
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Neoplasms
  • Osteosarcoma

abstract

  • The addition of ifosfamide in this dose schedule to standard chemotherapy did not enhance EFS. The addition of MTP to chemotherapy might improve EFS, but additional clinical and laboratory investigation will be necessary to explain the interaction between ifosfamide and MTP.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.06.031

PubMed ID

  • 15774791

Additional Document Info

start page

  • 2004

end page

  • 11

volume

  • 23

number

  • 9